• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Earnings Outlook At Henry Schein (HSIC) Has Changed Its Investment Story

    Simply Wall St·10/31/2026 17:28:30
    Listen to the news
    • Henry Schein is preparing to report quarterly results on November 3, with earnings per share expected to be slightly lower while revenue is projected higher, alongside a multi year plan that targets at least US$200 million of operating income improvement.
    • The push into shared services outsourcing and pricing analytics signals a deeper focus on trimming operating costs and supporting higher net margins in Henry Schein's distribution and services model.
    • We now examine how Henry Schein's investment narrative could be influenced by its earnings outlook and cost efficiency agenda.
    Spot opportunities beyond Henry Schein by scanning a curated 29 high quality undervalued stocks, which also combines operational efficiency stories with potential upside.

    Henry Schein Investment Narrative Recap

    To own Henry Schein, you need to be comfortable with a distributor that is leaning harder into higher margin technology and services while running a large cost takeout effort. The near term story revolves around whether the upcoming quarter confirms that revenue growth can coexist with slightly softer earnings per share as spending is reallocated into these value creation programs.

    The clearest short term catalyst is tangible progress on the plan to lift operating income by at least US$200 million, including evidence that shared services outsourcing and pricing analytics are scaling as intended. The biggest risk is that pricing pressure in digital dental equipment and lower scanner selling prices offset mix benefits, which would dilute the margin improvement investors are watching for.

    The multi year operating efficiency program is the announcement that matters most against this earnings backdrop. Management is targeting at least US$200 million of operating income improvement over the next few years, with a US$125 million run rate by the end of 2026. For a business that produced US$13.6b of revenue and US$403 million of net income, that is a meaningful swing factor.

    For you as a shareholder, the key question is execution. If Henry Schein can convert shared services outsourcing, pricing analytics, and high margin segment growth into cleaner overhead lines, the result would be a different earnings profile than a traditional distributor. If those projects slip, the narrative around operating leverage and the appeal of the cost efficiency story would weaken quickly.

    What Henry Schein’s Analyst Assumptions Really Imply

    Analysts are not just sketching a vague upside story for Henry Schein. They have put numbers on what the next stretch needs to look like, and those figures frame how much room for error you might be willing to tolerate in the execution of the cost and mix shift plan.

    On the top line, the consensus view calls for revenue to rise by 4.2% a year over the next few years, which would take sales to US$15.4b by 2029. That pace is not extreme for a distributor with both mature accounts and newer SaaS style subscription streams. It does, however, assume that dental equipment pricing pressure and any slowdown in procedure volumes do not chip away meaningfully at that trajectory.

    Earnings expectations are more demanding. The same analysts who model that 4.2% yearly revenue climb are forecasting profit to move from US$403.0 million today to US$661.2 million by 2029. That is roughly a US$258 million step up in earnings, which relies on the multi year operating income improvement program and a shift toward higher margin technology and specialty products showing through cleanly in reported margins.

    Valuation assumptions tie these operating goals back to what you pay for Henry Schein today. To land at a US$98.19 price target, analysts are effectively saying that by 2029, the business would be generating US$15.4b of revenue and US$661.2 million of earnings while trading on a 17.4x P/E ratio that is lower than both the current P/E multiple for the stock and the broader US healthcare sector.

    The implied path is not free of tension. A lower future P/E of 17.4x compared with 23.6x today bakes in some multiple compression. This means more of the investment case rests on delivery of the margin and earnings story rather than expansion of what investors are willing to pay per dollar of profit.

    Henry Schein's narrative projects US$15.4b revenue and US$661.2 million earnings by 2029. This view rests on 4.2% yearly revenue growth and roughly US$258 million earnings increase from US$403.0 million today.

    Uncover how Henry Schein's fair value indicates a 16% potential upside to its current price before a closing of the discount resets expectations.

    NasdaqGS:HSIC 1-Year Stock Price Chart
    NasdaqGS:HSIC 1-Year Stock Price Chart

    Exploring Other Perspectives

    For a very different angle on Henry Schein, look at the most bearish analysts who focus on execution risk on the outsourcing plan. They were pencilling in revenue of about US$15.1b and earnings of US$637.3 million by 2029, on a 13.7x P/E. That is a far harsher narrative than consensus, and the upcoming earnings update could shift either camp’s view.

    Explore another Henry Schein fair value estimate, including one that suggests it could be worth just $98.19.

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond Henry Schein?

    If Henry Schein's cost efficiency story has you thinking about portfolio balance, this is a good moment to widen the search. You can use the Simply Wall St Screener to filter for other stocks that match your risk tolerance, income needs, or appetite for mispriced opportunities.